NL154598B
(nl)
|
1970-11-10 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
|
US3817837A
(en)
|
1971-05-14 |
1974-06-18 |
Syva Corp |
Enzyme amplification assay
|
US3939350A
(en)
|
1974-04-29 |
1976-02-17 |
Board Of Trustees Of The Leland Stanford Junior University |
Fluorescent immunoassay employing total reflection for activation
|
US3996345A
(en)
|
1974-08-12 |
1976-12-07 |
Syva Company |
Fluorescence quenching with immunological pairs in immunoassays
|
US4277437A
(en)
|
1978-04-05 |
1981-07-07 |
Syva Company |
Kit for carrying out chemically induced fluorescence immunoassay
|
US4275149A
(en)
|
1978-11-24 |
1981-06-23 |
Syva Company |
Macromolecular environment control in specific receptor assays
|
US4366241A
(en)
|
1980-08-07 |
1982-12-28 |
Syva Company |
Concentrating zone method in heterogeneous immunoassays
|
US4472509A
(en)
|
1982-06-07 |
1984-09-18 |
Gansow Otto A |
Metal chelate conjugated monoclonal antibodies
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
WO1986005807A1
(en)
|
1985-04-01 |
1986-10-09 |
Celltech Limited |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
US4938948A
(en)
|
1985-10-07 |
1990-07-03 |
Cetus Corporation |
Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
EP1541682A3
(en)
|
1988-09-02 |
2005-07-06 |
Dyax Corp. |
Generation and selection of recombinant varied binding proteins
|
US7328387B2
(en)
|
2004-12-10 |
2008-02-05 |
Texas Instruments Incorporated |
Addressable tap domain selection circuit with selectable ⅗ pin interface
|
US5780225A
(en)
|
1990-01-12 |
1998-07-14 |
Stratagene |
Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
|
AU7247191A
(en)
|
1990-01-11 |
1991-08-05 |
Molecular Affinities Corporation |
Production of antibodies using gene libraries
|
JPH049249A
(ja)
|
1990-04-27 |
1992-01-14 |
Kusuda:Kk |
塗型剤吹き付け機
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
EP0580737B1
(en)
|
1991-04-10 |
2004-06-16 |
The Scripps Research Institute |
Heterodimeric receptor libraries using phagemids
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
WO1993011236A1
(en)
|
1991-12-02 |
1993-06-10 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
AU696293B2
(en)
|
1993-12-08 |
1998-09-03 |
Genzyme Corporation |
Process for generating specific antibodies
|
DK0744958T3
(da)
|
1994-01-31 |
2003-10-20 |
Univ Boston |
Polyklonale antistofbiblioteker
|
US5516637A
(en)
|
1994-06-10 |
1996-05-14 |
Dade International Inc. |
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
US5672694A
(en)
|
1995-10-24 |
1997-09-30 |
University Of Iowa Research Foundation |
β-sarcoglycan nucleic acid sequence, and nucleic acid probes
|
JP2978435B2
(ja)
|
1996-01-24 |
1999-11-15 |
チッソ株式会社 |
アクリロキシプロピルシランの製造方法
|
DE69731289D1
(de)
|
1996-03-18 |
2004-11-25 |
Univ Texas |
Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US20030181692A1
(en)
|
1997-06-06 |
2003-09-25 |
Jian Ni |
207 human secreted proteins
|
US20060223077A1
(en)
|
1997-06-06 |
2006-10-05 |
Human Genome Sciences, Inc. |
207 human secreted proteins
|
US20030060612A1
(en)
|
1997-10-28 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ATE458007T1
(de)
|
1998-04-20 |
2010-03-15 |
Glycart Biotechnology Ag |
Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
|
US6914130B2
(en)
|
1998-06-17 |
2005-07-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
SE9804180L
(sv)
|
1998-12-03 |
2000-01-24 |
Scania Cv Ab |
Anordning för ventilation av ett utrymme i ett fordon
|
US6962980B2
(en)
|
1999-09-24 |
2005-11-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6468546B1
(en)
|
1998-12-17 |
2002-10-22 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of ovarian cancer
|
US7888477B2
(en)
|
1998-12-17 |
2011-02-15 |
Corixa Corporation |
Ovarian cancer-associated antibodies and kits
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
EP2264166B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
US7504256B1
(en)
|
1999-10-19 |
2009-03-17 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing polypeptide
|
US20040142361A1
(en)
|
1999-11-30 |
2004-07-22 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of breast cancer
|
WO2001040269A2
(en)
|
1999-11-30 |
2001-06-07 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of breast cancer
|
US20020146727A1
(en)
|
1999-11-30 |
2002-10-10 |
Dillon Davin C. |
Compositions and methods for the therapy and diagnosis of breast cancer
|
AU2001245308A1
(en)
|
2000-02-24 |
2001-09-03 |
Human Genome Sciences, Inc. |
207 human secreted proteins
|
MXPA03000105A
(es)
|
2000-06-28 |
2004-09-13 |
Glycofi Inc |
Metodo para producir glicoproteinas modificadas.
|
CA2406649A1
(en)
|
2000-06-30 |
2002-01-10 |
Human Genome Sciences, Inc. |
B7-like polynucleotides, polypeptides, and antibodies
|
AU2001283507A1
(en)
|
2000-07-27 |
2002-02-13 |
Mayo Foundation For Medical Education And Research |
B7-h3 and b7-h4, novel immunoregulatory molecules
|
EP1311662A2
(en)
|
2000-08-24 |
2003-05-21 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
KR20030029847A
(ko)
|
2000-08-24 |
2003-04-16 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
CA2424977C
(en)
|
2000-10-06 |
2008-03-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
DK2314686T4
(da)
|
2000-10-06 |
2023-08-21 |
Kyowa Kirin Co Ltd |
Celler, der danner antistofsammensætninger
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
US20030087250A1
(en)
|
2001-03-14 |
2003-05-08 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
|
US7705120B2
(en)
|
2001-06-21 |
2010-04-27 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
WO2003011878A2
(en)
|
2001-08-03 |
2003-02-13 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
WO2005062788A2
(en)
|
2003-12-22 |
2005-07-14 |
Avalon Pharmaceuticals, Inc. |
Prostate specific proteins expressed in cancer and methods of use thereof
|
WO2003104399A2
(en)
|
2002-06-07 |
2003-12-18 |
Avalon Pharmaceuticals, Inc |
Cancer-linked gene as target for chemotherapy
|
WO2005035724A2
(en)
|
2003-10-08 |
2005-04-21 |
Avalon Pharmaceuticals, Inc |
Cancer-linked genes as targets for chemotherapy
|
AU2003213743A1
(en)
|
2002-03-06 |
2003-09-22 |
Avalon Pharmaceuticals |
Cancer-linked gene as target for chemotherapy
|
WO2003078637A2
(en)
|
2002-03-19 |
2003-09-25 |
Plant Research International B.V. |
Optimizing glycan processing in plants
|
US20040014194A1
(en)
|
2002-03-27 |
2004-01-22 |
Schering Corporation |
Beta-secretase crystals and methods for preparing and using the same
|
AU2003229294A1
(en)
|
2002-05-15 |
2003-12-02 |
Avalon Pharmaceuticals |
Cancer-linked gene as target for chemotherapy
|
AU2003229293A1
(en)
|
2002-05-16 |
2003-12-02 |
Avalon Pharmaceuticals |
Cancer-linked gene as target for chemotherapy
|
CA2488284A1
(en)
|
2002-06-04 |
2003-12-11 |
Avalon Pharmaceuticals, Inc. |
Cancer-linked gene as target for chemotherapy
|
CA2489198A1
(en)
|
2002-06-11 |
2003-12-18 |
Avalon Pharmaceuticals, Inc. |
Cancer-linked gene as target for chemotherapy
|
AU2003245615A1
(en)
|
2002-06-20 |
2004-01-06 |
The Regents Of The University Of California |
Compositions and methods for modulating lymphocyte activity
|
AU2003301167A1
(en)
|
2002-12-20 |
2004-07-22 |
Avalon Pharmaceuticals, Inc. |
Breast specific protein expressed in cancer and methods of use thereof
|
PL224786B1
(pl)
|
2003-01-22 |
2017-01-31 |
Glycart Biotechnology Ag |
Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza
|
CA2525899C
(en)
|
2003-05-09 |
2016-03-08 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
WO2004113500A2
(en)
|
2003-06-16 |
2004-12-29 |
The University Of Washington |
B7s1: an immune modulator
|
WO2005052121A2
(en)
|
2003-11-21 |
2005-06-09 |
Archemix Corp. |
Multivalent aptamers
|
WO2006074418A2
(en)
|
2005-01-07 |
2006-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP5173428B2
(ja)
|
2004-11-10 |
2013-04-03 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
US8188232B1
(en)
|
2004-11-15 |
2012-05-29 |
Washington University In St. Louis |
Compositions and methods for modulating lymphocyte activity
|
CA2601677A1
(en)
|
2005-03-11 |
2006-09-21 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
EP3058955B1
(en)
|
2005-03-24 |
2019-05-29 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind ov064 and methods of use therefor
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
US20090118175A1
(en)
|
2005-05-06 |
2009-05-07 |
Macina Roberto A |
Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
|
MX2007013924A
(es)
|
2005-05-09 |
2008-01-28 |
Glycart Biotechnology Ag |
Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
|
ES2608316T3
(es)
|
2005-06-08 |
2017-04-07 |
Dana-Farber Cancer Institute, Inc. |
Métodos y composiciones para el tratamiento del cáncer e infecciones persistentes mediante la inhibición de la ruta de la muerte celular 1 (PD-1) programada
|
JP2006345852A
(ja)
|
2005-06-16 |
2006-12-28 |
Virxsys Corp |
抗体複合体
|
JP5252635B2
(ja)
|
2005-07-01 |
2013-07-31 |
メダレックス インコーポレーティッド |
プログラム死リガンド1(pd−l1)に対するヒトモノクローナル抗体
|
JP5714212B2
(ja)
|
2005-12-08 |
2015-05-07 |
メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. |
O8eに対するヒトモノクローナル抗体
|
WO2007082154A2
(en)
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
US7884264B2
(en)
|
2006-01-17 |
2011-02-08 |
Biolex Therapeutics, Inc. |
Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in duckweed plants
|
KR101516823B1
(ko)
|
2006-03-17 |
2015-05-07 |
바이오겐 아이덱 엠에이 인코포레이티드 |
안정화된 폴리펩티드 조성물
|
US9121853B2
(en)
|
2006-03-20 |
2015-09-01 |
Mayo Foundation For Medical Education And Research |
B7-H4 expression on tumor vasculature
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
WO2007124361A2
(en)
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
WO2008051919A2
(en)
|
2006-10-23 |
2008-05-02 |
Acco Brands Usa Llc |
Security apparatus
|
US8444971B2
(en)
|
2006-11-27 |
2013-05-21 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
US8907065B2
(en)
|
2006-12-15 |
2014-12-09 |
Ablynx N.V. |
Polypeptides that modulate the interaction between cells of the immune system
|
EP2586458B1
(en)
|
2006-12-27 |
2016-08-24 |
The Johns Hopkins University |
Compositions and methods for treating inflammation and auto-immune diseases
|
AU2008261951A1
(en)
|
2007-06-08 |
2008-12-18 |
Asuragen, Inc. |
miR-34 regulated genes and pathways as targets for therapeutic intervention
|
CA2693677C
(en)
|
2007-07-12 |
2018-02-13 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
DK2188313T3
(en)
|
2007-08-21 |
2017-12-11 |
Amgen Inc |
HUMAN C-FMS ANTI-BINDING PROTEINS
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
MX344415B
(es)
|
2007-09-14 |
2016-12-15 |
Adimab Inc |
Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
|
JP2011505372A
(ja)
|
2007-11-30 |
2011-02-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
抗b7h4モノクローナル抗体−薬物コンジュゲートおよび使用方法
|
WO2009111315A2
(en)
|
2008-02-29 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing granulomatous inflammation
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
AU2010286351A1
(en)
|
2009-08-31 |
2012-03-15 |
Amplimmune, Inc. |
B7-H4 fusion proteins and methods of use thereof
|
CN102574924A
(zh)
|
2009-09-03 |
2012-07-11 |
先灵公司 |
抗-gitr抗体
|
EP2542588A1
(en)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
TWI713942B
(zh)
|
2010-05-04 |
2020-12-21 |
美商戊瑞治療有限公司 |
與集落刺激因子1受體(csf1r)結合之抗體類
|
US20120014947A1
(en)
|
2010-07-16 |
2012-01-19 |
The University Of Chicago |
Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
|
WO2012009568A2
(en)
|
2010-07-16 |
2012-01-19 |
Adimab, Llc |
Antibody libraries
|
WO2012130831A1
(en)
|
2011-03-29 |
2012-10-04 |
Roche Glycart Ag |
Antibody fc variants
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
WO2012145568A1
(en)
|
2011-04-21 |
2012-10-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Antibodies to human b7x for treatment of metastatic cancer
|
SI2703486T1
(en)
|
2011-04-25 |
2018-05-31 |
Daiichi Sankyo Company, Limited |
ANTI-B7-H3 PROTITELO
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
AU2012344260B2
(en)
|
2011-11-28 |
2017-09-07 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
JP2016505843A
(ja)
|
2012-12-19 |
2016-02-25 |
アンプリミューン, インコーポレイテッド |
B7−h4特異的抗体、並びにその組成物及び使用方法
|
SG10201709290XA
(en)
|
2012-12-21 |
2018-01-30 |
Medimmune Llc |
Anti-H7cr Antibodies
|
PE20151672A1
(es)
|
2013-03-14 |
2015-11-27 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
AU2014265142A1
(en)
|
2013-05-17 |
2015-12-24 |
Medimmune, Llc |
Receptors for B7-H4
|
KR102516152B1
(ko)
|
2013-08-01 |
2023-03-31 |
파이브 프라임 테라퓨틱스, 인크. |
비푸코실화된 항-fgfr2iiib 항체
|
JP2016531907A
(ja)
|
2013-08-02 |
2016-10-13 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. |
免疫刺激のためのcd27アゴニストと免疫チェックポイント阻害との組み合わせ
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
KR20160093012A
(ko)
|
2013-11-05 |
2016-08-05 |
코그네이트 바이오서비시즈, 인코포레이티드 |
암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
|
US10689432B2
(en)
|
2013-12-18 |
2020-06-23 |
Albert Einstein College Of Medicine |
B7X and its derivatives for treating and preventing cardiovascular disease
|
WO2015100219A1
(en)
|
2013-12-23 |
2015-07-02 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
WO2015112534A2
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
JP6682498B2
(ja)
|
2014-03-24 |
2020-04-15 |
キャンサー・リサーチ・テクノロジー・リミテッドCancer Research Technology Limited |
アゴニストまたはアンタゴニスト性を誘発する修飾されたIgG2ドメインを含む修飾された抗体及びその使用
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗-b7-h4抗體及免疫結合物
|
CA2964363A1
(en)
|
2014-10-17 |
2016-04-21 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators
|
WO2016070001A1
(en)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
AU2016243126A1
(en)
|
2015-03-27 |
2017-11-02 |
University Of Southern California |
CAR T-cells for the treatment of B7-H4 expressing solid tumors
|
PT3283508T
(pt)
|
2015-04-17 |
2021-06-21 |
Alpine Immune Sciences Inc |
Proteínas imuno modulatórias com afinidades afináveis
|
RS60753B1
(sr)
|
2015-04-17 |
2020-10-30 |
Bristol Myers Squibb Co |
Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
|
WO2016197204A1
(en)
|
2015-06-11 |
2016-12-15 |
Bionomics Limited |
Pharmaceutical combination and uses thereof
|
JP6913682B2
(ja)
|
2015-07-23 |
2021-08-04 |
インヒブリックス, インコーポレイテッド |
多価および多重特異性gitr結合融合タンパク質
|
GEP20227419B
(en)
|
2015-07-30 |
2022-10-10 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
CN108513576A
(zh)
|
2015-09-14 |
2018-09-07 |
高山免疫科学股份有限公司 |
可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
|
WO2017058754A1
(en)
|
2015-09-28 |
2017-04-06 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
PE20181300A1
(es)
|
2015-11-02 |
2018-08-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
US10918737B2
(en)
|
2016-01-28 |
2021-02-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancer
|
WO2017147368A1
(en)
|
2016-02-24 |
2017-08-31 |
Oncomed Pharmaceuticals, Inc. |
Redirecting immune responses
|
EP3423087B1
(en)
|
2016-03-04 |
2023-11-15 |
IO Biotech APS |
Combination therapy against cancer
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
ES2905823T3
(es)
|
2016-05-20 |
2022-04-12 |
Biohaven Therapeutics Ltd |
Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres
|
AU2017326751A1
(en)
|
2016-09-16 |
2019-03-14 |
Bionomics Limited |
Antibody and checkpoint inhibitor combination therapy
|
US10042000B2
(en)
|
2016-10-13 |
2018-08-07 |
Stmicroelectronics (Grenoble 2) Sas |
Method and apparatus for high frequency analog-to-digital conversion
|
SG11201903407XA
(en)
|
2016-10-20 |
2019-05-30 |
Alpine Immune Sciences Inc |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
GB201618291D0
(en)
|
2016-10-28 |
2016-12-14 |
Bergen Teknologioverf�Ring As |
Novel immunotherapeutic treatments for tumours
|
CN110662770A
(zh)
|
2016-11-23 |
2020-01-07 |
比奥维拉迪维治疗股份有限公司 |
结合凝血因子ix和凝血因子x的双特异性抗体
|
PE20190921A1
(es)
|
2016-12-07 |
2019-06-26 |
Agenus Inc |
Anticuerpos y metodos de su utilizacion
|
JP6992068B2
(ja)
|
2016-12-07 |
2022-02-03 |
アジェナス インコーポレイテッド |
抗ctla-4抗体およびそれらの使用方法
|
JP7437301B2
(ja)
|
2017-08-25 |
2024-02-22 |
ファイヴ プライム セラピューティクス インク |
B7-h4抗体及びその使用方法
|
EP3755719A1
(en)
*
|
2018-02-21 |
2020-12-30 |
Five Prime Therapeutics, Inc. |
B7-h4 antibody dosing regimens
|
CA3091174A1
(en)
*
|
2018-02-21 |
2019-08-29 |
Five Prime Therapeutics, Inc. |
B7-h4 antibody formulations
|
SG11202008105RA
(en)
|
2018-03-02 |
2020-09-29 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
CA3114955A1
(en)
|
2018-10-15 |
2020-04-23 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|